gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 20 Nov 2014.

V-raf murine sarcoma viral oncogene homolog B1

BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, CAN, Raf, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
New
Impact
Gonzalez et al., Nashville, United States. In J Clin Oncol, 20 Dec 2014
PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors.
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.
New
Weeraratna et al., Philadelphia, United States. In Pigment Cell Melanoma Res, 19 Dec 2014
We have also shown that Wnt5A promotes resistance to therapy designed to target the BRAF(V600E) mutation in melanoma.
MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
New
Buisine et al., Lille, France. In Int J Cancer, 18 Dec 2014
We quantified DNA methylation of mucin genes (MUC2, MUC5AC, MUC4) in colonic cancers and examined the association with clinicopathological characteristics and molecular (MSI, KRAS, BRAF and TP53 mutations) features.
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib.
New
Impact
Schadendorf et al., Aş Şanamayn, Syria. In N Engl J Med, 16 Dec 2014
UNLABELLED: Background The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.
Annexin A10 is a marker for the serrated pathway of colorectal carcinoma.
New
Mäkinen et al., Oulu, Finland. In Virchows Arch, 14 Dec 2014
BRAF V600E mutation correlated with ANXA10 expression but also seven BRAF wild-type tumors (5 %) were positive for ANXA10.
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
New
Impact
Ribas et al., Bergamo, Italy. In N Engl J Med, 13 Dec 2014
BACKGROUND: The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone.
Anchored multiplex PCR for targeted next-generation sequencing.
New
Impact
Le et al., Boston, United States. In Nat Med, 10 Dec 2014
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma.
Review
New
Karagiannis et al., London, United Kingdom. In Mol Cancer Ther, 10 Dec 2014
Almost 50% of melanomas harbor targetable activating mutations of BRAF that promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation.
Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.
Review
New
Middleton et al., Oxford, United Kingdom. In Ther Adv Med Oncol, 30 Nov 2014
The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma.
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy.
Review
New
van Amerongen et al., Amsterdam, Netherlands. In Cancer Res, 15 Nov 2014
UNLABELLED: Mutations in BRAF are present in the majority of patients with melanoma, rendering these tumors sensitive to targeted therapy with BRAF and MEK inhibitors.
Review of the current targeted therapies for non-small-cell lung cancer.
Review
New
Wakelee et al., Stanford, United States. In World J Clin Oncol, 10 Nov 2014
Emerging therapies directed against other driver oncogenes in NSCLC including ROS1, HER2, and BRAF are covered as well.
Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
New
Impact
Malek et al., San Francisco, United States. In Cancer Cell, 08 Oct 2014
Numerous oncogenic mutations occur within the BRAF kinase domain (BRAF(KD)).
Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma.
Review
New
Kim, Taegu, South Korea. In Endocrinol Metab (seoul), Sep 2014
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-γ, may carry diagnostic and prognostic significance.
Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib.
New
Oberholzer et al., Bern, Switzerland. In Case Rep Dermatol, Sep 2014
UNLABELLED: BRAF inhibitors are broadly used for metastatic melanoma with BRAF mutations.
Clonal architectures and driver mutations in metastatic melanomas.
New
Weber et al., Saint Louis, United States. In Plos One, Dec 2013
Significantly mutated gene analysis using 13 WGS cases and 15 additional paired extension cases identified known melanoma genes such as BRAF, NRAS, and CDKN2A, as well as a novel gene EPHA3, previously implicated in other cancer types.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
GeneRIF
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
GeneRIF
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Review
GeneRIF
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
GeneRIF
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
GeneRIF
Ozkinay et al., İzmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends